Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCKBR | P32239 | 3/20 | 0.44 |
| ▸ | CCR1 | P32246 | 7/20 | 0.44 |
| ▸ | CCR10 | P46092 | 1/20 | 0.42 |
| ▸ | TACR1 | P25103 | 1/20 | 0.40 |
| ▸ | MARK3 | P27448 | 1/20 | 0.40 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.38 |
| ▸ | ACE | P12821 | 2/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL181907 | 1.00 | CCKBR (0.44) | CCKBRCCR1CCR10TACR1MARK3 | |
| SCHEMBL181979 | 0.91 | CCKBR (0.47) | CCKBRCCR1CCR10TACR1MARK3 | |
| SCHEMBL15640652 | 0.89 | CCR1 (0.44) | CCKBRCCR1CCR10TACR1 | |
| SCHEMBL181489 | 0.89 | CCKBR (0.44) | CCKBRCCR1CCR10CALCRLACE | |
| SCHEMBL181490 | 0.89 | CCKBR (0.44) | CCKBRCCR1CCR10CALCRLACE | |
| SCHEMBL15640653 | 0.89 | CCR1 (0.44) | CCKBRCCR1CCR10TACR1 | |
| SCHEMBL181914 | 0.88 | CCKBR (0.42) | CCKBRCCR1CCR10TACR1MARK3 | |
| SCHEMBL181915 | 0.88 | CCKBR (0.42) | CCKBRCCR1CCR10TACR1MARK3 | |
| SCHEMBL181940 | 0.88 | CCR1 (0.42) | CCKBRCCR1CCR10TACR1CALCRL | |
| SCHEMBL181941 | 0.88 | CCR1 (0.42) | CCKBRCCR1CCR10TACR1CALCRL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2401268-B1 | OXYINDOLE DERIVATIVES WITH MOTILIN RECEPTOR AGONISTIC ACTIVITY | RAQUALIA PHARMA INC (JP) | 2015-07-29 | — | — | EP | disclosed |
| US-8697877-B2 | Oxyindole derivatives with motilin receptor agonistic activity | RAQUALIA PHARMA INC. (JP) | 2014-04-15 | — | — | US | disclosed |
| EP-2401268-A1 | OXYINDOLE DERIVATIVES WITH MOTILIN RECEPTOR AGONISTIC ACTIVITY | RaQualia Pharma Inc (JP) | 2012-01-04 | — | — | EP | disclosed |
| US-20110312933-A1 | OXYINDOLE DERIVATIVES WITH MOTILIN RECEPTOR AGONISTIC ACTIVITY | RAQUALIA PHARMA INC. (JP) | 2011-12-22 | — | — | US | disclosed |
| WO-2010098145-A1 | OXYINDOLE DERIVATIVES WITH MOTILIN RECEPTOR AGONISTIC ACTIVITY | RAQUALIA PHARMA INC. (JP) | 2010-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312933-A1 | OXYINDOLE DERIVATIVES WITH MOTILIN RECEPTOR AGONISTIC ACTIVITY | GPR68, GPR88, GPR52 | CCKBR 55/4885CCR1 1404/4885CCR10 1638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.